Is Coherus BioSciences Stock a Good Investment?
Coherus BioSciences Investment Advice | CHRS |
- Examine Coherus BioSciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Coherus BioSciences' leadership team and their track record. Good management can help Coherus BioSciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Coherus BioSciences' business and its evolving consumer preferences.
- Compare Coherus BioSciences' performance and market position to its competitors. Analyze how Coherus BioSciences is positioned in terms of product offerings, innovation, and market share.
- Check if Coherus BioSciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Coherus BioSciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Coherus BioSciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Coherus BioSciences is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Coherus BioSciences Stock
Researching Coherus BioSciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 58.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.09. Coherus BioSciences last dividend was issued on the June 26, 1995. The entity had 2:1 split on the December 8, 1992.
To determine if Coherus BioSciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Coherus BioSciences' research are outlined below:
| Coherus BioSciences generated a negative expected return over the last 90 days | |
| Coherus BioSciences has high historical volatility and very poor performance | |
| Coherus BioSciences has some characteristics of a very speculative penny stock | |
| Coherus BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 257.24 M. Net Loss for the year was (237.89 M) with profit before overhead, payroll, taxes, and interest of 136.08 M. | |
| Coherus BioSciences currently holds about 275.48 M in cash with (174.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Coherus BioSciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Insider Trading |
Coherus BioSciences Quarterly Cash And Short Term Investments |
|
Coherus BioSciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Coherus BioSciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Coherus BioSciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Coherus BioSciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Coherus BioSciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-06 | 2021-03-31 | 0.07 | 0.01 | -0.06 | 85 | ||
2024-05-09 | 2024-03-31 | -0.24 | -0.32 | -0.08 | 33 | ||
2020-11-05 | 2020-09-30 | 0.41 | 0.33 | -0.08 | 19 | ||
2023-08-02 | 2023-06-30 | -0.48 | -0.38 | 0.1 | 20 | ||
2018-11-08 | 2018-09-30 | -0.77 | -0.87 | -0.1 | 12 | ||
2024-11-06 | 2024-09-30 | -0.12 | -0.01 | 0.11 | 91 | ||
2021-02-24 | 2020-12-31 | 0.23 | 0.12 | -0.11 | 47 | ||
2021-11-08 | 2021-09-30 | -0.22 | -0.34 | -0.12 | 54 |
Know Coherus BioSciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Coherus BioSciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Coherus BioSciences backward and forwards among themselves. Coherus BioSciences' institutional investor refers to the entity that pools money to purchase Coherus BioSciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Aqr Capital Management Llc | 2024-12-31 | 1.2 M | |
| Los Angeles Capital Management Llc | 2024-12-31 | 1.1 M | |
| Millennium Management Llc | 2024-12-31 | 1 M | |
| Northern Trust Corp | 2024-12-31 | 1 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 976.9 K | |
| Macquarie Group Ltd | 2024-12-31 | 900 K | |
| Hudson Bay Capital Management Lp | 2024-12-31 | 835 K | |
| Tejara Capital Ltd | 2024-12-31 | 738.2 K | |
| Ubs Group Ag | 2024-12-31 | 709 K | |
| Vanguard Group Inc | 2024-12-31 | 11.2 M | |
| Blackrock Inc | 2024-12-31 | 11.1 M |
Coherus BioSciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 115.31 M.Market Cap |
|
Coherus BioSciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.78) | (0.82) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 1.41 | 1.97 |
Determining Coherus BioSciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Coherus BioSciences is a good buy. For example, gross profit margin measures Coherus BioSciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Coherus BioSciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Coherus BioSciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Coherus BioSciences. Check Coherus BioSciences' Beneish M Score to see the likelihood of Coherus BioSciences' management manipulating its earnings.
Evaluate Coherus BioSciences' management efficiency
Coherus BioSciences has return on total asset (ROA) of (0.1403) % which means that it has lost $0.1403 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.97 in 2025, whereas Return On Tangible Assets are likely to drop (0.40) in 2025. At this time, Coherus BioSciences' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 86.1 M in 2025, whereas Total Current Assets are likely to drop slightly above 311.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.36) | (2.24) | |
| Tangible Book Value Per Share | (3.24) | (3.08) | |
| Enterprise Value Over EBITDA | (3.21) | (3.05) | |
| Price Book Value Ratio | (1.46) | (1.53) | |
| Enterprise Value Multiple | (3.21) | (3.05) | |
| Price Fair Value | (1.46) | (1.53) | |
| Enterprise Value | 622.4 M | 539.3 M |
The strategic initiatives led by Coherus BioSciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.925 |
Basic technical analysis of Coherus Stock
As of the 8th of March, Coherus BioSciences shows the Mean Deviation of 4.69, standard deviation of 6.55, and Risk Adjusted Performance of (0.01). Coherus BioSciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Coherus BioSciences mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Coherus BioSciences is priced correctly, providing market reflects its regular price of 1.04 per share. Given that Coherus BioSciences is a hitting penny stock territory we recommend to closely look at its jensen alpha.Coherus BioSciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coherus BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coherus BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coherus BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coherus BioSciences' Outstanding Corporate Bonds
Coherus BioSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coherus BioSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coherus bonds can be classified according to their maturity, which is the date when Coherus BioSciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Coherus BioSciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Coherus BioSciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 4.69 | |||
| Coefficient Of Variation | (4,454) | |||
| Standard Deviation | 6.55 | |||
| Variance | 42.9 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.5712 | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 37.41 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.3 | |||
| Skewness | 1.24 | |||
| Kurtosis | 3.0 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 4.69 | |||
| Coefficient Of Variation | (4,454) | |||
| Standard Deviation | 6.55 | |||
| Variance | 42.9 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.5712 | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 37.41 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.3 | |||
| Skewness | 1.24 | |||
| Kurtosis | 3.0 |
Consider Coherus BioSciences' intraday indicators
Coherus BioSciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Coherus BioSciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Coherus BioSciences time-series forecasting models is one of many Coherus BioSciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Coherus BioSciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Coherus Stock media impact
Far too much social signal, news, headlines, and media speculation about Coherus BioSciences that are available to investors today. That information is available publicly through Coherus media outlets and privately through word of mouth or via Coherus internal channels. However, regardless of the origin, that massive amount of Coherus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Coherus BioSciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coherus BioSciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coherus BioSciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coherus BioSciences alpha.
Coherus BioSciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Coherus BioSciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Coherus BioSciences Corporate Management
| Vladimir Vexler | Chief Scientific Officer | Profile | |
| Bryan Mcmichael | Principal Accounting | Profile | |
| Michael Chen | Senior Trade | Profile | |
| Theresa Lavallee | Chief Board | Profile | |
| MRCP MD | Chief Officer | Profile | |
| Rebecca Sunshine | Chief Officer | Profile |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.